2022 MIPS Measure #366: Follow-Up Care for Children Prescribed ADHD Medication (ADD)

Description

Percentage of children 6-12 years of age and newly dispensed a medication for attention-deficit/hyperactivity disorder (ADHD) who had appropriate follow-up care. Two rates are reported.

a. Percentage of children who had one follow-up visit with a practitioner with prescribing authority during the 30-Day Initiation Phase.

b. Percentage of children who remained on ADHD medication for at least 210 days and who, in addition to the visit in the Initiation Phase, had at least two additional follow-up visits with a practitioner within 270 days (9 months) after the Initiation Phase ended.

Initial Population

Initial Population 1: Children 6-12 years of age who were dispensed an ADHD medication during the Intake Period and who had a visit during the measurement period.

Initial Population 2: Children 6-12 years of age who were dispensed an ADHD medication during the Intake Period and who remained on the medication for at least 210 days out of the 300 days following the IPSD, and who had a visit during the measurement period.

Denominator

Equals Initial Population

Denominator Exclusions

  • Denominator Exclusion 1: Exclude patients diagnosed with narcolepsy at any point in their history or during the measurement period.
  • Exclude patients who had an acute inpatient stay with a principal diagnosis of mental health or substance abuse during the 30 days after the IPSD.
  • Exclude patients who were actively on an ADHD medication in the 120 days prior to the Index Prescription Start Date.
  • Exclude patients who are in hospice care for any part of the measurement period.
  • Denominator Exclusion 2: Exclude patients diagnosed with narcolepsy at any point in their history or during the measurement period.
  • Exclude patients who had an acute inpatient stay with a principal diagnosis of mental health or substance abuse during the 300 days after the IPSD.
  • Exclude patients who were actively on an ADHD medication in the 120 days prior to the Index Prescription Start Date.
  • Exclude patients who are in hospice care for any part of the measurement period.

Numerator

Numerator 1: Patients who had at least one visit with a practitioner with prescribing authority within 30 days after the IPSD.

Numerator 2: Patients who had at least one visit with a practitioner with prescribing authority during the Initiation Phase, and at least two follow-up visits during the Continuation and Maintenance Phase.

Numerator Exclusions

Not Applicable

Denominator Exceptions

None


Tags

CMS-Mental-Behavioral-Health-2022, CMS-Pediatrics-2022, ecqm-2022, Psychiatry & Mental Health, Quality-2022